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Summary
Objective: To determine whether meniscal cells can express a TGF1 transgene delivered by a retroviral vector, and respond to the gene
product by increasing matrix synthesis.
Methods: Monolayer cultures of human and canine meniscal cells were infected with retroviruses carrying either a human TGF1 cDNA or
marker genes. Conditioned media were assayed for the presence of TGF1. Biosynthesis assays using radiolabeled precursors were
employed to determine the effects of the transgenes on the synthesis of proteoglycan, collagen and noncollagenous proteins. Collagen
phenotyping was performed by SDS-PAGE.
Results: Media conditioned by canine and human meniscal cells transduced with the TGF1 gene, accumulated several nanograms/106 cells
of TGF1 during a 48 h incubation. Media conditioned by control cells contained very little TGF1. Transduction with the TGF1 gene, but not
marker genes, increased the synthesis of collagen and proteoglycan by 8–15-fold. The synthesis of noncollagenous proteins was enhanced
more modestly. Monolayers of meniscal cells synthesized types I, III, V and VI collagen. The TGF1 gene increased the synthesis of all types
of collagen without altering the ratios between them.
Conclusions: Meniscal cells are readily transduced by retroviral vectors and respond to the transfer of a TGF1 cDNA by greatly increasing
matrix synthesis. These findings encourage the further development of genetic approaches to the healing of meniscal lesions. © 2000
OsteoArthritis Research Society International
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Gene therapy has much to offer the practice of orthopaed-
ics in general,1,2 and sports medicine in particular.3–5 Of
special interest is the prospect of improving the healing of
injured tissues by the local delivery of genes which encode
growth factors.1–5 Expression of such genes will result in
sustained, high concentrations of the growth factors at the
sites of injury, with minimal exposure of nontarget tissues.
Under the influence of these factors, the healing process
will be initiated, accelerated or otherwise improved. These
principles are being applied to the healing of articular
cartilage,6–11 bone,12–15 and ligaments and tendons.16–21
This paper describes results of relevance to their appli-
cation in treating meniscal injuries.
The inner two-thirds of the meniscus are avascular and
do not heal well. Various growth factors stimulate the
division of meniscal cells and increase matrix synthesis;
thus they hold promise as agents with which to improve
meniscal healing. Delivery of these factors is problematic,
and suitable delivery systems remain to be developed. As
described in the previous paragraph, gene transfer tech-
nologies offer elegant potential solutions to this problem.266We have recently demonstrated the feasibility of trans-
ferring a marker gene to sites of meniscal injury in lapine
and canine models.22 One gene transfer strategy
employed an adenoviral vector which was used to deliver
genes to cells within a fibrin clot implanted into the defect.
The other employed a retroviral vector which was used to
transfer genes to cultured meniscal cells which were then
placed within the lesion. In both cases, marker gene
expression persisted for several weeks.22
Having demonstrated the ability to transfer genes to
meniscal lesions, the next step is to determine which genes
will promote healing when used in this fashion. Here we
have evaluated a cDNA encoding transforming growth
factor-1 (TGF1), a protein which promotes the anabolic
activities of many types of connective tissue cells.23,24 The
addition of TGF1 protein to meniscal cells in culture has
been reported to stimulate their synthesis of collagen and
proteoglycan.25,26 Here we have confirmed this effect and
demonstrated that a similar response occurs in the
absence of added growth factor when the TGF1 gene is
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undergoing partial medial menisectomy for the treatment of
medial meniscal tears. The use of the human tissue was
approved by the local Institutional Review Board.
Tissues were diced into pieces approximately 3 mm long
and digested sequentially with 0.2% (w/v) trypsin and 0.2%
(w/v) collagenase for 3 h each at 37°C. The cells recovered
by this means were seeded into 25 cm2 plastic tissue
culture flasks (VWR Scientific, Bridgeport, NJ) with 4 ml of
Ham’s F12 medium supplemented with 10% fetal bovine
serum and antibiotics (GIBCO, Grand Island, NY).
TGF1 purified from human platelets (R&D Systems,
Minneapolis, MN), was added to certain cultures at concen-
trations indicated in the text.
GENE TRANSFER
A human TGF1 cDNA and the zeomycin resistance
gene were cloned into the backbone of the retrovirus DFG,
separated by an internal ribosome entry site. The resulting
virus is designated DFG-TGF1-zeor. Gene expression
was driven by the 5′ long terminal repeat of the retrovirus.
As a control, we used the BAG retrovirus27 which con-
tains the lacZ gene driven by the viral 5′ long terminal
repeat, and the neomycin resistance gene driven by the
SV40 early promoter. These vectors were generated by a
CRIP cell producer line.
For gene transfer, meniscal cell cultures were used at
60% confluence. Medium was removed, the cell sheet
washed once with Gey’s balanced salt solution (GIBCO,
Grand Island, NY) and 1 ml of retroviral vector suspension
was added in the presence of 8 g/ml polybrene (Sigma
Chemical Co., St Louis, MO). Cultures were incubated for
3 h with gentle shaking every 30 min. Three mls of fresh
medium were then added and the cells returned to the
incubator. The concentration of TGF1 in the conditioned
medium was determined by ELISA (R&D systems,
Minneapolis, MN) according to the manufacturer’s instruc-
tions. Latent TGF1 was activated by heating to 80°C for
15 min. Expression of the lacZ marker gene was detected
by histochemical staining with the chromogenic substrate
X-gal.
MATRIX SYNTHESIS
Synthesis of collagen and noncollagenous proteins was
measured quantitatively by the incorporation of [3H]-proline
into collagenase-sensitive proteins as described pre-
viously.28,29 Collagen typing was performed by separating
the [3H]-proline labeled collagen  chains by sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) under both nonreducing and reducing conditions,
using 7.5% acrylamide gels.29 After electrophoresis, gels
were treated with EN3HANCE (DuPont-NEN, Boston, MA)
and radioactive bands detected by autoradiography. The
densities of the bands representing the 1(I) and 2(I)
chains of type I collagen were quantified with an imaging
densitometer (model GS-670; BioRad Laboratories,
Richmond, CA).
Proteoglycan synthesis was measured by the incorpor-
ation of 35SO2−4 into glycosaminoglycans, as we have
described elsewhere in detail.30,31
One-way analysis of variance, followed by Fisher’s
protected least significant difference post-hoc testing, was
used to evaluate the data. A probability of P<0.05
was taken to indicate statistical significance.Results
EXPRESSION OF A TGF1 TRANSGENE BY MENISCAL CELLS
Canine and human meniscal fibrochondrocytes were
transduced with TGF1 and the concentration of TGF1 in
48 h conditioned media was determined using ELISA. As
shown in Fig. 1, large amounts of TGF1 were produced by
the cells infected with DFG-TGF1-zeor but not the control
cells or cells transduced with the control BAG virus.
Increased amounts of TGF1 were also produced in menis-
cal cells following transduction by an adenovirus carrying
the TGF1 gene (data not shown). After establishing that
meniscal cells could be successfully transduced with viral
vectors encoding TGF1, we assessed the effect of puri-
fied, human TGF1 protein and TGF1 produced endogen-
ously after viral transduction, on matrix synthesis in
monolayer cultures of canine and human meniscal cells.
STIMULATION OF MATRIX SYNTHESIS BY CANINE AND HUMAN
MENISCAL CELLS TRANSDUCED WITH TGF1 cDNA
Purified human TGF1 was added to monolayer cultures
of meniscal fibrochondrocytes and the synthesis of both
collagen and noncollagenous protein was measured. The
synthesis of both fractions was strongly stimulated in a
dose-dependent manner (Fig. 2). TGF1 induced greater
increases collagen synthesis than noncollagenous protein
synthesis in both canine and human cells. A marked
response of human cells occurred with as little as 1 ng/ml
TGF1, at which concentration collagen synthesis was
increased 5–6-fold. Canine cells required higher concen-
tration of TGF1 to reach a maximum response, achieving
an approximately 15-fold increase in collagen synthesis
and five-fold increase in noncollagenous protein synthesis
at 10 ng/ml TGF1. The differences in dose–response may
reflect the greater sensitivity of human cells to human
TGF1. Canine and human cells transduced with the
TGF1 gene also showed significant increases in collagen
and noncollagenous protein synthesis, with collagen syn-
thesis again being increased to a greater degree than
noncollagenous protein synthesis as had been observedFig. 1. Production of TGF1 by retrovirally transduced canine and
human meniscal cells. Monolayers were retrovirally transduced
with TGF1 or LacZ genes, or remained as untransduced controls.
48 hours later, media were recovered and TGF1 concentrations
measured by ELISA. Each culture contained 2×105 cells. Values
given are means±SD (N=6). *P<0.05 relative to control.
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fection (lacZ) did not change the basal level of protein
synthesis in human and canine cells.
The TGF1-induced increase in collagen synthesis was
further studied by collagen phenotyping. Figure 4 shows an
autoradiogram obtained following the separation by SDS-
PAGE of the collagens synthesized by canine meniscal
cells treated with purified TGF1 or by cells transduced with
the TGF1 gene. Meniscal cells in a monolayer culture
synthesized type I, type III, type V, and type VI collagens.
The presence of type III collagen was confirmed by SDS-
PAGE of the samples under reducing conditions (data not
shown). Densitometric scanning (data not shown) con-
firmed that TGF1 increased collagen synthesis without
altering the relative ratios of collagen types I, III, V and VI
(Fig. 4).
The addition of purified human TGF1 to canine and
human monolayer cultures of meniscal cells also produced
a dose-dependent increase in proteoglycan synthesis
(Fig. 5). Consistent with previous results is the observation
that human cells were more sensitive than canine cells to
human TGF1. After transducing canine and human cells
with the TGF1 gene, considerable increases in proteo-
glycan synthesis were also obtained (Fig. 6). In contrast to
the data shown in Fig. 5, canine cells appeared to be more
responsive to virally produced TGF1 than human cells,but this may be due to the higher basal incorporation of
35SO4 into glycosaminoglycans seen in human control cells(Fig. 6).Fig. 2. Effect of purified TGF1 on the synthesis of collagen and non-collagenous proteins by meniscal cells. TGF1 was added to monolayer
cultures at the indicated concentrations, and the incorporation of [3H]-proline into collagen and noncollagenous proteins measured. Values
are the average percent of control±SD (N=8 for canine cells; N=5 for human cells). *P<0.05 relative to control.Fig. 3. Effect of genetic transduction on the synthesis of collagen and non-collagenous proteins by meniscal cells. Monolayers were
retrovirally transduced with TGF1 or Lac Z genes, or remained as untreated controls. The incorporation of [3H]-proline into collagen and
noncollagenous proteins was then measured. Values given are the average percent of control±SD (N=8 for canine cells; N=5 for human
cells). *P<0.05 relative to control and Lac Z.Fig. 4. Autoradiogram of collagen chains synthesized by meniscal
cells after biosynthetic labeling with [3H]-proline and separation by
SDS-PAGE. Canine meniscal cells were transduced with TGF1 or
Lac Z genes. Media conditioned by cells transduced with the
TGF1 gene contained 0.96 ng/ml TGF1 protein. Untransduced
cells were treated with the indicated concentrations of purified
TGF1. [3H]-proline was added to cultures and the newly synthe-
sized collagen chains separated by SDS-PAGE and visualized by
autoradiography.
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These data establish the principle that meniscal cells can
be engineered to express a growth factor and respond to its
endogenous production by increasing matrix synthesis.
Used in conjunction with the methods we have described
for expressing genes within meniscal lesions,22 this prin-
ciple forms the basis of novel approaches to enhancing
meniscal repair by gene therapy.
The responses of meniscal cells to transduction by a
TGF1 cDNA are qualitatively similar to those exhibited by
articular chondrocytes9,11 and cells of the intervertebral
disc.32 Despite its ability to enhance matrix synthesis
by cartilaginous tissues TGF1 has potent inflammatory
properties when injected intraarticularly,33,34 or when its
cDNA is delivered to synovium.35 This suggests that any
clinically useful application of TGF gene transfer for
enhancing the repair of intraarticular, cartilaginous tis-
sues will require highly focused, intracartilaginous deliv-
ery to avoid triggering synovial reactions. Although ourexperiments demonstrate an impressive increase in total
proteoglycan synthesis by transduced meniscal cells, the
data are quantitative and therefore do not reveal whether
the synthesis of all classes of proteoglycan was increased
coordinately. This matter requires further study.
Although this paper reports only the evaluation of
TGF1 as a therapeutic gene, there are a number of
other growth factors meriting attention in this context,
including the fibroblast growth factors, insulin-like growth
factors, bone morphogenetic proteins, cartilage-derived
growth and differentiation factors, hepatocyte growth fac-
tor and so forth.36–38 To the degree that excessive matrix
degradation limits meniscal repair, it will also be useful to
transfer genes whose products antagonize the catabolic
activities of cells within the meniscus. Antagonists of
interleukin-1 and tumor necrosis factor should be useful in
this regard. Much further research is required to deter-
mine which gene or combination of genes provides the
best healing response.
In addition to identifying the appropriate genes, a
successful gene therapy approach to healing meniscal
injuries requires optimization of the gene delivery system
as well as the level and duration of gene expression. So
far, adenoviral vectors have been used to deliver a
marker gene by direct injection into the meniscus and by
infection of blood cells within a clot which was subse-
quently inserted into the lesion. A third experimental route
involved the retroviral infection of meniscal cells which
were embedded in a collagen gel and then implanted.22
Direct injection of adenovirus is technically the simplest
method, but it only transduced a small number of menis-
cal cells unless damage to the meniscus had provoked
matrix loss, thereby exposing more cells. Based on
experience with articular cartilage, it is possible that cer-
tain other vectors, such as neutral liposomes containing
hemagglutinating virus of Japan (Sendai virus) may be
able to diffuse through the extracellular matrix of menis-
cus and transfect cells in situ.39 Both the ex vivo methods
evaluated in our earlier study,22 although more tedious
than in vivo strategies, successfully transferred a marker
gene to the lesion, where gene expression persisted for
several weeks. Future investigations will determine
whether this length of gene expression is sufficient for the
repair of damaged menisci.
The results described in this paper encourage further
development of genetic approaches to the healing of
meniscal lesions.Fig. 5. Effect of purified TGF1 on the synthesis of proteoglycan by
meniscal cells. TGF1 was added to monolayer cultures at the
indicated concentrations, and its effects on the incorporation of
35SO2−4 into GAGs was measured. *P<0.05 relative to untreated
control (N=6).Fig. 6. Effect of genetic transduction on the synthesis of proteoglycan by meniscal cells. Monolayers were retrovirally transduced with TGF1
or Lac Z genes, or remained as untreated controls. The incorporation of 35SO2−4 into GAGs was then measured. *P<0.05 relative to control
and Lac Z (N=6).
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